Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.37 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | SDCBP | O00560 | 1/20 | 0.37 |
| ▸ | SDC2 | P34741 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 2/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MMP7 | P09237 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 3/20 | 0.36 |
| ▸ | FPR2 | P25090 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3834577 | 1.00 | MEN1 (0.38) | MEN1KMT2ANPC1RAB9AITGB1 | |
| SCHEMBL7412293 | 1.00 | MEN1 (0.38) | MEN1KMT2ANPC1RAB9AITGB1 | |
| SCHEMBL4600067 | 0.92 | CTRB1 (0.40) | NPC1RAB9AITGB1ITGA4PPARG | |
| SCHEMBL5407004 | 0.92 | CTRB1 (0.40) | NPC1RAB9AITGB1ITGA4PPARG | |
| SCHEMBL4600752 | 0.92 | CTRB1 (0.40) | NPC1RAB9AITGB1ITGA4PPARG | |
| SCHEMBL30510366 | 0.92 | CTRB1 (0.40) | NPC1RAB9AITGB1ITGA4PPARG | |
| SCHEMBL25177964 | 0.90 | ATM (0.39) | MEN1KMT2AITGB1ITGA4ITGB7 | |
| SCHEMBL30767800 | 0.90 | ATM (0.39) | MEN1KMT2AITGB1ITGA4ITGB7 | |
| SCHEMBL5403825 | 0.90 | ITGA4 (0.42) | ITGB1ITGA4ITGB7PPARGPPARA | |
| SCHEMBL7105951 | 0.89 | NPC1 (0.38) | NPC1RAB9AITGB1ITGA4PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1235595-B8 | INTEGRIN-MEDIATED DRUG TARGETING | BAYER SCHERING PHARMA AG (DE) | 2009-10-07 | — | — | EP | disclosed |
| US-7220824-B1 | Integrin-mediated drug targeting | BAYER AKTIENGESELLSCHAFT (DE) | 2007-05-22 | — | — | US | disclosed |
| US-20060189544-A1 | Integrin-Mediated drug targeting | BAYER AKTIENGESELLSCHAFT (DE) | 2006-08-24 | — | — | US | disclosed |
| US-7094911-B2 | Biphenyl and biphenyl-analogous compounds as integrin antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2006-08-22 | — | — | US | disclosed |
| EP-1140809-B1 | NEW BIPHENYL AND BIPHENYL-ANALOGOUS COMPOUNDS AS INTEGRIN ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2005-08-31 | — | — | EP | disclosed |
| US-20040229859-A1 | Beta-amino acid compounds as integrin antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2004-11-18 | — | — | US | disclosed |
| US-6794386-B2 | β-amino acid compounds as integrin antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2004-09-21 | — | — | US | disclosed |
| US-20040030132-A1 | New biphenyl and biphenyl-analogous compounds as integrin antagonists | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-02-12 | — | — | US | disclosed |
| US-20040029883-A1 | Beta-amino acid compounds as integrin antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2004-02-12 | — | — | US | disclosed |
| US-6677360-B2 | TREATMENT AND PROPHYLAXIS OF CANCER, ARTERIOSCLEROSIS, RESTENOSIS, OSTEOPOROSIS AND EYE DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2004-01-13 | — | — | US | disclosed |
| EP-1246800-A1 | BETA-AMINO ACID COMPOUNDS AS INTEGRIN ANTAGONISTS | Bayer Aktiengesellschaft (DE) | 2002-10-09 | — | — | EP | disclosed |
| EP-1235595-A2 | INTEGRIN-MEDIATED DRUG TARGETING | Bayer Aktiengesellschaft (DE) | 2002-09-04 | — | — | EP | disclosed |
| US-6420396-B1 | TREATMENT OF CANCER, ARTERIOSCLEROSIS, RESTENOSIS, OSTEOLYTIC DISORDERS, OPHTHALMIC DISORDERS, AND THEIR USE AS INTEGRIN ANTAGONISTS. INHIBITING ANGIOGENESIS | BEIERSDORF AG (DE) | 2002-07-16 | — | — | US | disclosed |
| US-20020016461-A1 | Biphenyl and biphenyl-analogous compounds as integrin antagonists | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2002-02-07 | — | — | US | disclosed |
| CN-1334801-A | Biphenyl and biphenyl-analogous compounds as integrin antagonists | BAYER AG (DE) | 2002-02-06 | — | — | CN | disclosed |
| EP-1140809-A1 | NEW BIPHENYL AND BIPHENYL-ANALOGOUS COMPOUNDS AS INTEGRIN ANTAGONISTS | Bayer Aktiengesellschaft (DE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001047887-A1 | β-AMINO ACID COMPOUNDS AS INTEGRIN ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-05 | — | — | WO | disclosed |
| WO-2001017563-A2 | INTEGRIN-MEDIATED DRUG TARGETING | BAYER AKTIENGESELLSCHAFT (DE) | 2001-03-15 | — | — | WO | disclosed |
| WO-2000035864-A1 | NEW BIPHENYL AND BIPHENYL-ANALOGOUS COMPOUNDS AS INTEGRIN ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040030132-A1 | New biphenyl and biphenyl-analogous compounds as integrin antagonists | ITGB2, ITGB1, ITGB3 | MEN1 2380/4885KMT2A 2495/4885NPC1 2378/4885 |
| US-20040029883-A1 | Beta-amino acid compounds as integrin antagonists | ITGB2, ITGA2, ITGA2B | MEN1 4769/4885KMT2A 1867/4885NPC1 4078/4885 |
| US-20040229859-A1 | Beta-amino acid compounds as integrin antagonists | ITGB1, ITGA1, ITGAL | MEN1 4563/4885KMT2A 3785/4885NPC1 4663/4885 |
| US-20060189544-A1 | Integrin-Mediated drug targeting | ITGAV, ITGB3, ITGB1 | MEN1 2199/4885KMT2A 3929/4885NPC1 3654/4885 |
| US-20020016461-A1 | Biphenyl and biphenyl-analogous compounds as integrin antagonists | ITGB1, ITGB2, ITGB3 | MEN1 2649/4885KMT2A 2324/4885NPC1 2358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.